Skip to main content
SpringerLink
Log in

The Epidemiology of Pan/Extreme Drug Resistance

  • Chapter
  • First Online:
Antibiotic Policies

Abstract

Multidrug resistance in Gram-negative bacilli is clearly of global concern. The purpose of this chapter is to review the epidemiology of organisms referred to as pan-resistant (PDR) or exhibiting extreme drug resistance (also referred to as extensive drug resistance—XDR). In order to better understand the epidemiology, it is first essential to define what is regarded as PDR or XDR.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  • Tseng S-P, Tsai J-C, Teng L-J, Hsueh P-R. Dissemination of transposon Tn6001 in carbapenem-non-susceptible and extensively drug-resistant Pseudomonas aeruginosa in Taiwan. Journal of Antimicrobial Chemotherapy 2009 ;64(6):1170-4.

    Article  PubMed  CAS  Google Scholar 

  • Poirel L, Lagrutta E, Taylor P, Pham J, Nordmann P. Emergence of metallo-ß-lactamase NDM-1-producing multidrug resistant Escherichia coli in Australia. Antimicrob Agents Chemother 2010 54(11):4914-6.

    Google Scholar 

  • Park YK, Peck KR, Cheong HS, Chung DR, Song JH, Ko KS. Extreme drug resistance in Acinetobacter baumannii infections in intensive care units, South Korea. Emerg Infect Dis 2009 Aug;15(8):1325-7.

    Article  PubMed  Google Scholar 

  • Doi Y, Husain S, Potoski BA, McCurry KR, Paterson DL. Extensively drug-resistant Acinetobacter baumannii. Emerg Infect Dis 2009; 15(6):980-2.

    Article  PubMed  Google Scholar 

  • Grosso F, Quinteira S, Peixe L. Emergence of an extreme-drug-resistant (XDR) Acinetobacter baumannii carrying blaOXA-23 in a patient with acute necrohaemorrhagic pancreatitis. Journal of Hospital Infection 2010;75(1):82-3.

    Article  PubMed  CAS  Google Scholar 

  • Falagas ME, Rafailidis PI, Matthaiou DK, Virtzili S, Nikita D, Michalopoulos A. Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: Characteristics and outcome in a series of 28 patients. International Journal of Antimicrobial Agents 2008;32(5):450-4.

    Article  PubMed  CAS  Google Scholar 

  • Antoniadou A, Kontopidou F, Poulakou G, et al. Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster. J Antimicrob Chemother 2007;59(4):786-90.

    Google Scholar 

  • Lee J, Patel G, Huprikar S, Calfee DP, Jenkins SG. Decreased Susceptibility to Polymyxin B during Treatment for Carbapenem-Resistant Klebsiella pneumoniae Infection. J Clin Microbiol 2009; 47(5):1611-2.

    Article  PubMed  Google Scholar 

  • Samonis G, Matthaiou Dimitrios K, Kofteridis D, Maraki S, Falagas Matthew E. In Vitro Susceptibility to Various Antibiotics of Colistin†Resistant Gram†Negative Bacterial Isolates in a General Tertiary Hospital in Crete, Greece. Clinical Infectious Diseases 2010;50(12):1689-91.

    Google Scholar 

  • Tóth Á, Damjanova I, Puskás E, et al. Emergence of a colistin-resistant KPC-2-producing Klebsiella pneumoniae ST258 clone in Hungary. European Journal of Clinical Microbiology & Infectious Diseases 2010;29(7):765-9.

    Article  Google Scholar 

  • Elemam A, Rahimian J, Mandell W. Infection with panresistant Klebsiella pneumoniae: a report of 2 cases and a brief review of the literature. Clin Infect Dis 2009 15;49(2):271-4.

    Article  PubMed  Google Scholar 

  • Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. The Lancet Infectious Diseases 2010;10(9):597-602.

    Article  PubMed  CAS  Google Scholar 

  • Picazo JJ, Betriu C, Rodriguez-Avial I, Culebras E, Gomez M, Lopez F. Antimicrobial resistance surveillance: VIRA STUDY 2006. Enferm Infecc Microbiol Clin 2006; 24(10):617-28.

    Article  Google Scholar 

  • Korten V, Ulusoy S, Zarakolu P, Mete B. Antibiotic resistance surveillance over a 4-year period (2000-2003) in Turkey: results of the MYSTIC Program. Diagnostic Microbiology and Infectious Disease 2007;59(4):453-7.

    Article  PubMed  CAS  Google Scholar 

  • Garrison MW, Mutters R, Dowzicky MJ. In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: Tigecycline Evaluation and Surveillance Trial 2004 to 2007. Diagnostic Microbiology and Infectious Disease 2009;65(3):288-99.

    Article  PubMed  CAS  Google Scholar 

  • Hawser SP, Bouchillon SK, Hoban DJ, Badal RE. In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli from patients with intra-abdominal infections worldwide from 2005-2007: results from the SMART study. International Journal of Antimicrobial Agents 2009;34(6):585-8.

    Article  PubMed  CAS  Google Scholar 

  • Norskov-Lauritsen N, Marchandin H, Dowzicky MJ. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007). Int J Antimicrob Agents 2009 ight countries in the Asia-Western Pacific region;34(2):121-30.

    Article  Google Scholar 

  • WHONET Greece. http://www.mednet.gr/whonet/.

    Google Scholar 

  • Farrell DJ, Turnidge JD, Bell J, Sader HS, Jones RN. The in vitro evaluation of tigecycline tested against pathogens isolated in eight countries in the Asia-Western Pacific region (2008). J Infect 2010 ;60(6):440-51.

    Article  Google Scholar 

  • Wang H, Chen M, Ni Y, et al. Antimicrobial resistance among clinical isolates from the Chinese Meropenem Surveillance Study (CMSS), 2003-2008. International Journal of Antimicrobial Agents 2010;35(3):227-34.

    Article  PubMed  CAS  Google Scholar 

  • Hsueh P-R, Badal RE, Hawser SP, et al. Epidemiology and antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2008 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). International Journal of Antimicrobial Agents 2010;36(5):408-14.

    Google Scholar 

  • Bantar C, Curcio D, Fernandez Canigia L, Garcia P, Guzman Blanco M, Leal AL. Comparative in vitro activity of tigecycline against bacteria recovered from clinical specimens in Latin America. J Chemother 2009 ;21(2):144-52.

    PubMed  CAS  Google Scholar 

  • Reinert RR, Low DE, Rossi Fv, Zhang X, Wattal C, Dowzicky MJ. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. Journal of Antimicrobial Chemotherapy 2007;60(5):1018-29.

    Article  PubMed  CAS  Google Scholar 

  • Dowzicky MJ, Park CH. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: Results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007. Clinical Therapeutics 2008;30(11):2040-50.

    Article  PubMed  CAS  Google Scholar 

  • Jones RN, Kirby JT, Rhomberg PR. Comparative activity of meropenem in US medical centers (2007): initiating the 2nd decade of MYSTIC program surveillance. Diagnostic Microbiology and Infectious Disease 2008;61(2):203-13.

    Article  PubMed  CAS  Google Scholar 

  • Yamaguchi K, Ohno A, Ishii Y, et al. In vitro susceptibilities to levofloxacin and various antibacterial agents of 12,919 clinical isolates obtained from 72 centers in 2007. Jpn J Antibiot 2009 ;62(4):346-70.

    PubMed  CAS  Google Scholar 

  • Jean SS, Hsueh PR, Lee WS, et al. Nationwide surveillance of antimicrobial resistance among non-fermentative Gram-negative bacteria in Intensive Care Units in Taiwan: SMART programme data 2005. Int J Antimicrob Agents 2009 ;33(3):266-71.

    Google Scholar 

  • Wang YF, Dowzicky MJ. In vitro activity of tigecycline and comparators on Acinetobacter spp. isolates collected from patients with bacteremia and MIC change during the Tigecycline Evaluation and Surveillance Trial, 2004 to 2008. Diagn Microbiol Infect Dis 2010 Sep;68(1):73-9.

    Article  PubMed  CAS  Google Scholar 

  • Hawser SP, Badal RE, Bouchillon SK, Hoban DJ, the SIWG. Antibiotic susceptibility of intra-abdominal infection isolates from Indian hospitals during 2008. J Med Microbiol 2010; 59(9):1050-4.

    Google Scholar 

  • Paterson DL . The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006; 43 Suppl. 2:S43–48.

    Google Scholar 

  • Paterson DL, Doi Y . A step closer to extreme drug resistance (XDR) in gram-negative bacilli. Clin Infect Dis 2007; 45(9):1179–81.

    Article  PubMed  Google Scholar 

  • Falagas ME, Karageorgopoulos DE. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: Need for international harmonization in terminology. Clin Infect Dis 2008; 46(7): 1121–22.

    Article  PubMed  Google Scholar 

  • Europe Centre for Disease Prevention and Control (ECDC). Multi drug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance.

    Google Scholar 

  • European Centre for Disease Prevention and Control (ECDC). http://ecdc.europa.eu/en/activities/surveillance/EARS-Net/database/Pages/table_reports.aspx

  • Kumarasamy KK. Lancet Infectious Diseases 2010;10(9):597–602.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The University of Queensland, UQ Centre for Clinical Research, Herston, Brisbane, Australia

    Yoshiro Hayashi & David L. Paterson

  2. Department of Intensive Care Medicine, Royal Brisbane and Women’s Hospital, Herston, Brisbane, Australia

    Yoshiro Hayashi

Authors
  1. Yoshiro Hayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David L. Paterson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoshiro Hayashi .

Editor information

Editors and Affiliations

  1. Medical School, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, United Kingdom

    Ian M. Gould

  2. University Hospital Nijmegen, Nijmegen, Netherlands

    Jos W.M. van der Meer

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Hayashi, Y., Paterson, D.L. (2012). The Epidemiology of Pan/Extreme Drug Resistance. In: Gould, I., van der Meer, J. (eds) Antibiotic Policies. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-1734-8_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-1734-8_3

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4419-1733-1

  • Online ISBN: 978-1-4419-1734-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation